Cardiome Expects Anti-Arrhythmic NDA Submission By 2006

In a Phase III study, 52% of patients with recent onset atrial fibrillation converted to normal heart rhythm compared to 4% for placebo. RSD1235 could merit premium pricing over Wyeth’s Cordarone and amiodarone generics, Cardiome CEO says.